Ibex Therapeutics
IBEX Therapeutics, a Swiss company specialised in therapies based on biological products derived from plant extracts.
Lugaia
With Swiss precision and cutting-edge technology for innovative and customised product and personal protection, we focus on life sciences, pharmaceuticals and biotechnology. Lugaia is driving forward the development of complete containment solutions – from the initial idea and ergonomic study to the manufacture of complex isolator systems.
DePoly
Cleantech start-up DePoly is behind an innovative solution to the plastics challenge facing the world today.
Based at the Energypolis Campus in Sion and supported by The Ark Foundation, DePoly is now building its demonstration plant on the Monthey chemical site and extending its activities to the BioArk Monthey technology site to follow the construction work.
Regen Lab
RegenLab® is recognized as a certified global leader in medical biotechnologies, specializing in autologous platelet-rich plasma treatment.
RegenLab® is at the forefront of innovation, with an expertly designed medical device for the preparation of platelet rich plasma from the patient’s own blood.
Regen® A-PRP® was developed with a focus on product quality, patient safety, and preparation efficiency. Our patient-centered technology has led to over two million treatments provided worldwide using RegenLab® products. As we look to the future, the company is committed to guiding new standards for emerging categories within the field of regenerative medicine.
Bioscibex
Bioscibex is at the forefront of biopharmaceutical innovation, providing cutting-edge bioreactor technologies that simplify and automate cell-based therapies. We aim to accelerate and reduce the cost of drug development and manufacturing, making breakthrough treatments accessible to all and improving global health and longevity. Our single-use bioreactor simplifies cell culture with automation and closed system, accommodating volumes from 30 mL to 30 L in the same vessel. It is designed for a broad range of cells. Our technology offers an unmatched scalability (bioreactor’s 1000:1 turndown ratio), advanced sensors, modularity and a proven technology.
Precise Health
Precise Health is a biotech startup aiming to revolutionize the treatment of bacterial infections by replacing broad-spectrum antibiotics with personalized bacteriophage technology – starting with inflammatory skin conditions.
Precise Health platform’s leverages the specificity and selectivity of bacteriophages, microorganisms able to target and eliminate harmful bacteria while preserving the beneficial microbiota hence significantly reducing the likelihood of developing antimicrobial resistance.
Ninsun Biotech
Ninsun Biotech is a start-up based in Valais at BioArk. It operates in the field of oncology and is revolutionising the marking of cancer stem cells by offering, for the first time, a specific biomarker for several cancers, including lung, breast and colon. Current technologies rely on the use of a combination of non-specific markers, so Ninsun Biotech is breaking new ground with its patented technology, offering new prospects in terms of diagnosis, monitoring (companion tests) and, ultimately, individualised treatment for patients. Ninsun Biotech’s stem cell marking kits are also perfectly compatible with the current clinical chain of patient management.
Adryan AG
Adryan is an internationally operating services group. From their offices in The Netherlands and Switzerland, Adryan offer a full range of services for the (Bio-) Pharmaceutical and High-End Food industry. They distinguish themselves in the areas of Project Management, Engineering, CQV and Compliance.
Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease and VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
Stämm
The Argentine company specializes in the development of microfluidic systems for biomanufacturing.
